# A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES

> **NIH NIH N01** · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2024 · $1,089,350

## Abstract

The goal of this contract project is to develop the glycolipid-based adjuvant for human use, with initial indications for a malaria vaccine. The scope of our product development project is to develop our novel CD1d-binding natural killer T (NKT) cell-stimulatory glycolipid, called 7DW8-5, as a versatile vaccine adjuvant. Initial partner vaccines are based on a nucleic acid-based priming and whole parasite-based boosting liver-targeted malaria vaccine. We have published that that the 7DW8-5 glycolipid significantly increases the immunogenicity and efficacy of the nucleic acid prime-and-parasite trap malaria vaccines in a mouse model and have additional data showing that the adjuvant simplifies formulation and administration of this vaccine. Here, we will evaluate non-GMP-grade 7DW8-5 for formulation, solubility, release, stability, and toxicology. We will also confirm safety, immunogenicity, and efficacy of the 7DW8-5/malaria vaccine in non-human primates (NHPs). Lastly, we will develop a pre-IND regulatory package for future 7DW8-5 FDA review.

## Key facts

- **NIH application ID:** 11127342
- **Project number:** 75N93023C00041-P00001-9999-1
- **Recipient organization:** COLUMBIA UNIVERSITY HEALTH SCIENCES
- **Principal Investigator:** MORIYA TSUJI
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $1,089,350
- **Award type:** —
- **Project period:** 2023-09-30 → 2028-09-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11127342

## Citation

> US National Institutes of Health, RePORTER application 11127342, A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES (75N93023C00041-P00001-9999-1). Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/grant/nih/11127342. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*